Intervention Protocol

You have free access to this content

Antidepressants for insomnia

  1. Hazel Everitt1,*,
  2. David S Baldwin2,
  3. Andrew Mayers3,
  4. Andrea L Malizia4,
  5. Sue Wilson5

Editorial Group: Cochrane Common Mental Disorders Group

Published Online: 11 OCT 2013

DOI: 10.1002/14651858.CD010753

How to Cite

Everitt H, Baldwin DS, Mayers A, Malizia AL, Wilson S. Antidepressants for insomnia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010753. DOI: 10.1002/14651858.CD010753.

Author Information

  1. 1

    University of Southampton, Primary Medical Care, Southampton, UK

  2. 2

    University of Southampton, School of Medicine, Southampton, UK

  3. 3

    Bournemouth University, Department of Psychology, School of Design, Engineering & Computing, Poole, UK

  4. 4

    The Burden Centre, Frenchay hospital, Department of Neurosurgery, Bristol, UK

  5. 5

    University of Bristol, Psychopharmacology Unit, Bristol, UK

*Hazel Everitt, Primary Medical Care, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, SO16 5ST, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 11 OCT 2013



Additional references

Altena 2008
Baglioni 2011
  • Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders 2011;135:1-19.
Balter 1992
Boin 2013
  • Boin AC, Baceti PA, Chambo RC, Rubira CJ, Carvalho MLM, de Oliveira Carvalho PE. Antihistamines for insomnia. Cochrane Database of Systematic Reviews in press.
Breslau 1996
Buscemi 2007
  • Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. Journal of General Internal Medicine 2007;22(9):1335-50.
Buysse 1989
Carvalho 2009
  • Aversa Lopes E, Silva AB, Macedo CR, Soares B, Saconato H, Atallah ÁN. Cognitive behavioural therapy for insomnia. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006814]
Cheuk 2012
Chevalier 1999
  • Chevalier H, Los F, Boichut D, Bianchi M, Nutt DJ, Hajak G, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. Journal of Psychopharmacology 1999;13(4 Suppl 1):21-4.
Edinger 2008
  • Edinger JD, Means MK, Carney CE, Krystal AD. Psychomotor performance deficits and their relation to prior nights' sleep among individuals with primary insomnia. Sleep 2008;31(5):599-607.
Heumann 2013
  • Heumann C, Hajak G, Rösner S. Valerian for insomnia. Cochrane Database of Systematic Reviews in press.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. Available from
Ishigooka 1999
Krystal 2003
  • Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26(7):793-9.
Krystal 2008
  • Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31(1):79-90.
Lai 2011
  • Lai L, Tan MH, Lai YC. Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. Drug, Healthcare and Patient Safety 2011;3:27-36.
LeBlanc 2009
  • LeBlanc M, Merette C, Savard J, Ivers H, Baillargeon L, Morin CM. Incidence and risk factors of insomnia in a population-based sample. Sleep 2009;32(8):1027-37.
Leger 2001
  • Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosomatic Medicine 2001;63(1):49-55.
Lemoine 2007
Mayer 2009
  • Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32(3):351-60.
Mayers 2005
Mellinger 1985
Moher 2009
Morin 1993
  • Morin CM. Insomnia: Psychological Assessment and Management. New York, USA: Guilford Press, 1993.
Morin 1999
  • Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. Journal of the American Medical Association 1999;281(11):991-9.
Morin 2003
Morlock 2006
  • Morlock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey data, 1997-2002. Clinical Therapeutics 2006;28(7):1044-53.
Neckelmann 2007
nhsuk 2011
  • nhsuk. Prescription Cost Analysis England 2010. 2011 (accessed June 2011).
NICE 2004
  • National Institute for Clinical Excellence (NICE). Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (Technology Appraisal 77) (accessed 12 Sep 2013). London: NICE, 2004; Vol.
NIH 1983
  • National institute of Health Consensus development programme. Drugs and Insomnia: The Use of Medications to Promote Sleep. 1983.
NIH 2005
  • NIH. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults []. Sleep 2005;28(9):1049-57.
Nissen 2011
Ohayon 1999
  • Ohayon MM, Caulet M, Arbus L, Billard M, Coquerel A, Guieu JD, et al. Are prescribed medications effective in the treatment of insomnia complaints?. Journal of Psychosomatic Research 1999;47(4):359-68.
Perlis 2010
  • Perlis M, Shaw P, Cano G, Espie C. Chapter 78: Models of Insomnia. In: Kryger M, Roth T, Dement W editor(s). Principles and Practice of Sleep Medicine. 5th Edition. St Louis, Missouri: Saunders, 2010:850-65.
Philip 2006
  • Philip P, Leger D, Taillard J, Quera-Salva MA, Niedhammer I, Mosqueda JG, et al. Insomniac complaints interfere with quality of life but not with absenteeism: respective role of depressive and organic comorbidity. Sleep Medicine 2006;7(7):585-91.
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Riemann 2009
  • Riemann D, Perlis, ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioural therapies. Sleep Medicine Reviews 2009;13:205-14.
Rösner 2013
  • Rösner S, Soyka M, Hajak G, Wehrle R. New generation hypnotics for insomnia. Cochrane Database of Systematic Reviews in press.
Saarto 2010
Sateia 2004
Sivertsen 2009
Vgontzas 2009
  • Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 2009;32(4):491-7.
Wade 2007
  • Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion 2007;23(10):2597-605.
Walsh 2007
  • Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30(8):959-68.
WHO 1992
  • World Health Organisation. ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation, 1992.
Wilson 2005
Wilson 2010
  • Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. Journal of Psychopharmacology 2010;24(11):1577-601.
Xu 2013